title: Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
abstract: There has been a 10-year hiatus in the approval of a new pharmacotherapy for patients with chronic heart failure with a reduced ejection fraction (HFrEF). Combining an angiotensin receptor blocker, valsartan, with sacubitril, an inhibitor of neprilysin, results in increasing levels of natriuretic peptides that counterbalance high circulating levels of neurohormones in HFrEF. This has resulted in the development of a new agent, LCZ696. A comprehensive overview of LCZ696, its pharmacology, its role in the pathophysiology of HFrEF, completed and future clinical trial information, specific critical issues, and the place of LCZ696 in HFrEF therapy are presented.
authors.affiliation: Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah.
authors.forename: Jordan B
authors.initials: JB
authors.lastname: King
authors.affiliation: Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah.|VA Salt Lake City Health Care System, Salt Lake City, Utah.
authors.forename: Adam P
authors.initials: AP
authors.lastname: Bress
authors.affiliation: Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah.
authors.forename: Austin D
authors.initials: AD
authors.lastname: Reese
authors.affiliation: Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah.|Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Munger
mesh_terms: D000613:Aminobutyrates / Q000494:pharmacology / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D001713:Biphenyl Compounds; D002908:Chronic Disease; D004338:Drug Combinations; D015195:Drug Design; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination
keywords: heart failure with reduced ejection fraction; neprilysin inhibition; pharmacotherapy; systolic heart failure; therapeutic review